#P2X3 - Twitter Hashtag

Carolyn Novaleski, Ph.D., CCC-SLP @novaleski

2 months ago

New Phase 1 study of #camlipixant, a selective #P2X3 receptor antagonist, evaluated the safety, tolerability, & pharmacokinetics (N=90 healthy adults). Findings support continued #drug development for #ChronicCough. Chauret et al. (2026) #ACCP 👇 🔗https://t.co/rXxCXLiWQf

novaleski's tweet photo. New Phase 1 study of #camlipixant, a selective #P2X3 receptor antagonist, evaluated the safety, tolerability, & pharmacokinetics (N=90 healthy adults).

Findings support continued #drug development for #ChronicCough.

Chauret et al. (2026) #ACCP
👇
🔗https://t.co/rXxCXLiWQf https://t.co/I5S09lENyJ

0

3

2

0

196

Journal of Physiology @JPhysiol

8 months ago

In this recent study, @DrCarolBussey and colleagues from @FMHS_UoA investigated anti-#arrhythmic targeting of sympathetic stellate ganglion #P2X3 receptors 🫀 🔬 Read the #Research: https://t.co/iTgTtUtcBv

JPhysiol's tweet photo. In this recent study, @DrCarolBussey and colleagues from @FMHS_UoA
investigated anti-#arrhythmic targeting of sympathetic stellate ganglion #P2X3 receptors 🫀 🔬

Read the #Research: https://t.co/iTgTtUtcBv https://t.co/kKIQ8WWVdo

0

1

0

437

Carolyn Novaleski, Ph.D., CCC-SLP @novaleski

almost 2 years ago

Thach et al. @PurdueBiolSci demonstrate #camlipixant targets #P2X3 receptors by blocking signals that trigger #coughing. Identified unique binding site w/ cryo-EM that might reduce coughing without affecting taste. #OpenAccess article in @jbiolchem ➡️ https://t.co/p9nTkVzvG0

novaleski's tweet photo. Thach et al. @PurdueBiolSci demonstrate #camlipixant targets #P2X3 receptors by blocking signals that trigger #coughing. Identified unique binding site w/ cryo-EM that might reduce coughing without affecting taste.

#OpenAccess article in @jbiolchem ➡️ https://t.co/p9nTkVzvG0 https://t.co/q6CCgweyQl

0

5

3

0

901

Mindaugas Galvosas, MD @MGalvosas

over 3 years ago

Chronic cough space has some serious movements - this time by @GSK and @BELLUSHealth #Cough #ChronicCough #P2X3 https://t.co/7XJFOByDM4

0

2

0

78

Juan C Ivancevich MD @Aller_MD

over 4 years ago

Will This #Chronic #Cough Drug Succeed Where Others Failed? — Phase II data show fewer side effects than with previous #P2X3 #inhibitors. https://t.co/YF3wUfREhX

0

2

4

0

MedChemExpress

@MedChemExpress

over 6 years ago

BLU-5937 is a #selective and orally active #P2X3 homotrimeric receptor #antagonist. BLU-5937 has a strong anti-tussive effect.#drugdiscovery. https://t.co/vKopfCmtYz

MedChemExpress's tweet photo. BLU-5937 is a #selective and orally active #P2X3 homotrimeric receptor #antagonist. BLU-5937 has a strong anti-tussive effect.#drugdiscovery. https://t.co/vKopfCmtYz https://t.co/VrdzvVg1eh

0

1

0

Biotech Jim

@JamesEKrause

over 6 years ago

@semodough @phatoftheland10 @Biohazard3737 @syinvesting The entire https://t.co/ZbHg92q2v2 data set on #gefapixant is revealing as to the overall approach with #P2X3 antagonists. https://t.co/dTPzoCt0ph That is the foresight of a good clinical research group.

0

2

0

Bayer AG @Bayer

about 7 years ago

Worldwide, around 10% of all women of childbearing age suffer from #endometriosis. Learn how our the investigational #P2X3 antagonist approach might improve the quality of life for affected patients through targeting mediators of excessive nerve signaling: https://t.co/oQytXONm0J

Bayer's tweet photo. Worldwide, around 10% of all women of childbearing age suffer from #endometriosis. Learn how our the investigational #P2X3 antagonist approach might improve the quality of life for affected patients through targeting mediators of excessive nerve signaling: https://t.co/oQytXONm0J https://t.co/Kh6W5opSFt

1

10

2

1

0

Roberto Bellini @rbellini

about 9 years ago

Many opioid medications for chronic cough that could be avoided as well with a better available treatment. #P2X3 @BELLUSHealth https://t.co/4QpX844Qxx

0

1

0